The rheumatology and gastroenterology biosimilar candidate would enter the lucrative market established by Humira.
Alvotech of Reykjavik, Iceland, said its adalimumab biosimilar candidate (AVT02) has been accepted for regulatory review by the FDA and the European Medicines Agency (EMA).
The drug references AbbVie’s top-selling Humira for the treatment of arthritis, psoriasis, ankylosing spondylitis, Crohn disease, and ulcerative colitis. The product candidate submitted for review is a high-concentration, 100-mg/mL dose form that matches the newest formulation of Humira, Alvotech said.
An FDA decision on the biologics license application is expected in September 2021, while the EMA decision whether to issue marketing authorization for AVT02 is anticipated in the fourth quarter of 2021, Alvotech said.
“The filings were based on the results of a comprehensive development program and data package comprising of a totality of evidence demonstrating a high degree of similarity of AVT02 compared to its reference product,” said Joseph E. McClellan, PhD, MBA, company chief scientific officer.
The pharmacokinetic (PK) study AVT02-GL-101 successfully established PK similarity between AVT02 and the reference product following subcutaneous administration of a single dose of 40 mg in healthy individuals, Alvotech said.
A second, comparative clinical efficacy and safety trial demonstrated therapeutic equivalence in patients with severe chronic psoriasis. Alvotech said safety, efficacy, tolerability, and immunogenicity profiles were similar.
“The comprehensive AVT02 development program has demonstrated key results comparatively to the reference product, and we are extremely happy to have met our primary objectives in regard to efficacy, safety, and PK similarities,” said Kimber Poffenberger, PhD, senior vice president and global head of Regulatory Affairs for Alvotech.
For recent news about Alvotech’s commercialization partnerships for the global marketing of its biosimilar candidates, click here.
Biosimilars Gastroenterology Roundup: March 2025
April 1st 2025As the biosimilar industry celebrates a decade of growth, the market continues to evolve with expanded treatment options, cost savings, and a flurry of new competitors—yet regulatory challenges, market dynamics, and patient accessibility remain key hurdles to unlocking its full potential.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Patients With IBD Maintain Therapy 2 Years Post Switching to Infliximab Biosimilar
March 23rd 2025People with inflammatory bowel disease (IBD) who switched to the infliximab biosimilar CT-P13 had higher treatment persistence (84% and 91%) than those new to infliximab (66% and 53%), with no new safety concerns.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Review Calls for Path to Global Harmonization of Biosimilar Development Regulations
March 17th 2025Global biosimilar regulatory harmonization will be needed to reduce development costs and improve patient access, despite challenges posed by differing national requirements and regulatory frameworks, according to review authors.
Comparable Pregnancy and Infant Milestones With Infliximab Biosimilars vs Originator in IBD
March 15th 2025A study evaluating pregnancy outcomes and infant developmental milestones found similar outcomes between pregnant women with inflammatory bowel disease (IBD) who received reference infliximab and those who received a biosimilar.